1. Academic Validation
  2. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

  • Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337.
Darren A E Cross 1 Susan E Ashton 2 Serban Ghiorghiu 2 Cath Eberlein 2 Caroline A Nebhan 3 Paula J Spitzler 3 Jonathon P Orme 4 M Raymond V Finlay 2 Richard A Ward 2 Martine J Mellor 2 Gareth Hughes 2 Amar Rahi 2 Vivien N Jacobs 2 Monica Red Brewer 3 Eiki Ichihara 3 Jing Sun 3 Hailing Jin 3 Peter Ballard 2 Katherine Al-Kadhimi 2 Rachel Rowlinson 2 Teresa Klinowska 2 Graham H P Richmond 2 Mireille Cantarini 2 Dong-Wan Kim 5 Malcolm R Ranson 6 William Pao 7
Affiliations

Affiliations

  • 1 Oncology Innovative Medicines and Darren.Cross@astrazeneca.com william.pao@vanderbilt.edu.
  • 2 Oncology Innovative Medicines and.
  • 3 Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and.
  • 4 Discovery Sciences, AstraZeneca, Macclesfield Cheshire;
  • 5 Seoul National University Hospital, Seoul, Republic of Korea.
  • 6 University of Manchester, Christie Hospital, Manchester, United Kingdom;
  • 7 Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and Darren.Cross@astrazeneca.com william.pao@vanderbilt.edu.
Abstract

First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical benefit in patients with advanced EGFR-mutant (EGFRm(+)) non-small cell lung Cancer (NSCLC). Patients ultimately develop disease progression, often driven by acquisition of a second T790M EGFR TKI resistance mutation. AZD9291 is a novel oral, potent, and selective third-generation irreversible inhibitor of both EGFRm(+) sensitizing and T790M resistance mutants that spares wild-type EGFR. This mono-anilino-pyrimidine compound is structurally distinct from other third-generation EGFR TKIs and offers a pharmacologically differentiated profile from earlier generation EGFR TKIs. Preclinically, the drug potently inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines, translating into profound and sustained tumor regression in EGFR-mutant tumor xenograft and transgenic models. The treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC is described as proof of principle.

Significance: We report the development of a novel structurally distinct third-generation EGFR TKI, AZD9291, that irreversibly and selectively targets both sensitizing and resistant T790M(+) mutant EGFR while harboring less activity toward wild-type EGFR. AZD9291 is showing promising responses in a phase I trial even at the first-dose level, with first published clinical proof-of-principle validation being presented.

Figures
Products